LiTES-HCC评分预测肝细胞癌肝移植后生存
评分纳入肿瘤与非肿瘤相关变量(如年龄、慢性肾病),在符合米兰和UCSF标准的患者中可区分移植后生存,未来可能用于等待名单优先级分配。
要点
- LiTES-HCC评分基于11个变量预测肝细胞癌肝移植后5年和10年生存。
- 5年和10年AUC分别为0.62(95%CI 0.57-0.67)和0.65(95%CI 0.58-0.72)。
- 评分在符合米兰和UCSF标准的患者中可区分移植后生存。
核心结论
- 开发并验证了LiTES-HCC评分,用于预测肝细胞癌患者肝移植后生存,纳入肿瘤与非肿瘤相关变量,未来可能整合至生存获益模型以优化等待名单优先级。
主要发现
- 最终模型纳入11个变量,5年和10年AUC分别为0.62(95%CI 0.57-0.67)和0.65(95%CI 0.58-0.72),与Metroticket和HALT-HCC评分无统计学显著差异。
- LiTES-HCC评分在符合米兰和UCSF标准的患者中可区分移植后生存。
关键数值与推荐
- 5年AUC为0.62(95%CI 0.57-0.67),10年AUC为0.65(95%CI 0.58-0.72)。
- 最终模型包含11个变量。
临床怎么用
- 该评分纳入肿瘤与非肿瘤相关变量(如年龄、慢性肾病),可帮助移植专业人员根据预测生存对肝细胞癌患者进行优先级排序。
- 未来该评分可能整合至基于生存获益的模型,以在人群水平改善生命年。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Liver transplant priority in the US and Europe follows the 'sickest-first' principle. However, for patients with hepatocellular carcinoma (HCC), priority is based on binary tumor criteria to expedite transplant for patients with 'acceptable' post-transplant outcomes. Newer risk scores developed to overcome limitations of these binary criteria are insufficient to be used for waitlist priority as they focus solely on HCC-related pre-transplant variables. We sought to develop a risk score to predict post-transplant survival for patients using HCC- and non-HCC-related variables. METHODS: We performed a retrospective cohort study using national registry data on adult deceased-donor liver transplant (DDLT) recipients with HCC from 2/27/02-12/31/18. We fit Cox regression models focused on 5- and 10-year survival to estimate beta coefficients for a risk score using manual variable selection. We then calculated absolute predicted survival time and compared it to available risk scores. RESULTS: Among 6,502 adult DDLT recipients with HCC, 11 variables were selected in the final model. The AUCs at 5- and 10-years were: 0.62, 95% CI 0.57-0.67 and 0.65, 95% CI 0.58-0.72, which was not statistically significantly different to the Metroticket and HALT-HCC scores. The LiTES-HCC score was able to discriminate patients based on post-transplant survival among those meeting Milan and UCSF criteria. CONCLUSION: We developed and validated a risk score to predict post-transplant survival for patients with HCC. By including HCC- and non-HCC-related variables (e.g., age, chronic kidney disease), this score could allow transplant professionals to prioritize patients with HCC in terms of predicted survival. In the future, this score could be integrated into survival benefit-based models to lead to meaningful improvements in life-years at the population level. LAY SUMMARY: We created a risk score to predict how long patients with liver cancer will live if they get a liver transplant. In the future, this could be used to decide which waitlisted patients should get the next transplant.
引用
- Goldberg D, Mantero A, Newcomb C, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma using the LiTES-HCC score. J Hepatol. 2021. PMID: 33453328. doi:10.1016/j.jhep.2020.12.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。